Fuzionaire Theranostics is a radiopharmaceutical company on a mission to make better and more accessible theranostic treatments for people with cancer. With origins in Nobel laureate Robert Grubbs' lab at Caltech, the company's patented HetSiFA® platform enables rapid development of radioligand therapies and companion PET diagnostics, and offers manufacturing advantages in a clinical setting. The company’s pipeline addresses pressing clinical needs for several types of cancer, beginning with cancers in which gastrin-releasing peptide receptor (GRPR) is expressed, including metastatic prostate cancer.